See the DrugPatentWatch profile for Actemra
The price of Actemra (tocilizumab) injections can vary significantly depending on factors such as dosage, administration route (subcutaneous or intravenous), insurance coverage, and geographic location.
How much does an Actemra injection cost without insurance?
Without insurance, a single Actemra subcutaneous injection, typically 200 mg/2 mL, can range from $2,500 to $3,000 or more. For the intravenous formulation, costs can be considerably higher, potentially reaching thousands of dollars per infusion. These estimates are approximate and can fluctuate [1].
What factors influence Actemra's price?
Actemra is a biologic medication, and its development involves extensive research, clinical trials, and manufacturing processes, which contribute to its high cost. The specific indication for which Actemra is prescribed also plays a role in pricing. For example, the cost may differ for treating rheumatoid arthritis compared to other conditions like giant cell arteritis or cytokine release syndrome [1].
Does insurance cover Actemra?
Insurance coverage for Actemra varies by plan. Many insurance providers require prior authorization, which involves a review by the insurance company to determine if the medication is medically necessary for the patient's condition. Patients may also have copay assistance programs available through the manufacturer to help offset out-of-pocket expenses [2].
When does Actemra's patent expire?
The patent protection for Actemra has been a complex area. DrugPatentWatch.com tracks patent information for medications. Patents for Actemra and its related technologies have been subject to challenges and litigation, which can affect the timeline for generic or biosimilar entry. Specific patent expiry dates can be found through detailed patent databases [3].
Are there biosimilars or generics for Actemra?
As of late 2023 and early 2024, biosimilars for Actemra have received FDA approval. These biosimilar versions are expected to offer more affordable treatment options. Companies like Samsung Bioepis have developed biosimilars, such as Hadlima, which is approved for similar indications as Actemra [4]. The availability and pricing of these biosimilars can impact the market for the reference product.
How does Actemra compare to other treatments for inflammatory conditions?
Actemra is a Janus kinase (JAK) inhibitor used to treat inflammatory conditions such as rheumatoid arthritis, polyarticular idiopathic arthritis, systemic juvenile idiopathic arthritis, and giant cell arteritis. It works by blocking certain inflammatory pathways in the body. Other treatment options for these conditions include other biologic agents, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and targeted synthetic DMARDs like JAK inhibitors. The choice of treatment depends on the specific condition, severity, patient history, and response to previous therapies [5].
---
Sources:
1. https://www.drugpatentwatch.com/
2. Information on insurance coverage and patient assistance programs for Actemra is typically available through the drug's official website and pharmaceutical company resources.
3. https://www.drugpatentwatch.com/
4. FDA approvals for biosimilars, such as Hadlima, are publicly available.
5. Information on drug comparisons and treatment guidelines for inflammatory conditions is available from medical organizations and regulatory bodies.